Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the dosing of the first patient in the intravenous infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial.
The OASIS trial is being conducted at the City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumours.
The OASIS trial combines a CD19-expressing oncolytic virus with a CD19-targeting drug.
Imugene said the trial aims to recruit 40 to 45 patients with metastasised advanced solid cancers, with preliminary early combination data expected in the fourth quarter of 2024.
Managing director and CEO Leslie Chong said, “We are pleased to enrol the first IV combination patient and further advance our OASIS trial, which combines our CD19 oncolytic virus with the already approved and marketed CD19 bispecific in patients with advanced solid cancers. While CD19 has been a powerful target for blood cancers, no such targets currently exist for solid cancers.
“We aspire to change that with onCARlytics, which causes cancers to display CD19 on their cell surface so that an approved CD19 therapeutics can target and kill the cancer. If successful, onCARlytics could open up 90 per cent of the market as CD19 products are only approved in blood cancer and provide a new treatment option for patients with solid tumours.”
